Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 629

The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.

ERS clinical practice guidelines on treatment of sarcoidosis

Open access
Baughman, Robert P., Valeyre, Dominique, Korsten, Peter, Mathioudakis, Alexander G., Wuyts, Wim A., Wells, Athol, Rottoli, Paola, Nunes, Hiliaro, Lower, Elyse E., Judson, Marc A., Israel-Biet, Dominique, Grutters, Jan C., Drent, Marjolein, Culver, Daniel A., Bonella, Francesco, Antoniou, Katerina, Martone, Filippo, Quadder, Bernd, Spitzer, Ginger, Nagavci, Blin, Tonia, Thomy, Rigau, David, Ouellette, Daniel R.·2021·European Respiratory Journal

Abstract

Background: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. Glucocorticoid-sparing alternatives are available. The presented treatment guidelines aim to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations. Methods: A European Respiratory Society Task Force committee composed of clinicians, methodologists and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations. Results: The Task Force committee delivered 12 recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac and neurologic disease as well as fatigue. One PICO question regarding small-fibre neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation. Conclusions: There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.04079-2020

Cites

184 of 184 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 60

  1. 10.1183/16000617.0145-2019 · doi:10.1183/16000617.0145-2019
  2. 10.1183/23120541.00141-2018 · doi:10.1183/23120541.00141-2018
  3. 10.1378/chest.128.2.1062 · DOI · Paper page
  4. 10.1093/qjmed/hcl038 · doi:10.1093/qjmed/hcl038
  5. 10.1212/WNL.0000000000004644 · doi:10.1212/wnl.0000000000004644
  6. 10.1378/chest.125.3.990 · doi:10.1378/chest.125.3.990
  7. Baughman, 2020, Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a 6 year period, Sarcoidosis Vasc Diffuse Lung Dis, 37, e2020001
  8. Drent, 2014, Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 31, 91
  9. Lower, 2020, Use of third-line therapies in advanced sarcoidosis, Clin Exp Rheumatol, 38, 834
  10. Baughman, 2004, Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 21, 43
  11. Muers, 1997, A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society study of long-term corticosteroid treatment, Sarcoidosis Vasc Diffuse Lung Dis, 14, 46
  12. 10.2165/00128071-200809030-00003 · doi:10.2165/00128071-200809030-00003
  13. 10.1183/13993003.00897-2019 · doi:10.1183/13993003.00897-2019
  14. 10.1016/S0140-6736(67)90493-X · doi:10.1016/s0140-6736(67)90493-x
  15. 10.1378/chest.116.2.424 · doi:10.1378/chest.116.2.424
  16. Zaki, 1987, Corticosteroid therapy in sarcoidosis: a 5 year controlled follow-up, NY State J Med, 87, 496
  17. 10.7326/0003-4819-73-2-207 · doi:10.7326/0003-4819-73-2-207
  18. 10.1111/j.1365-2796.1994.tb00798.x · doi:10.1111/j.1365-2796.1994.tb00798.x
  19. Baughman, 2002, Use of fluticasone in acute symptomatic pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 19, 198
  20. Baughman, 2014, Features of sarcoidosis associated with chronic disease, Sarcoidosis Vasc Diffuse Lung Dis, 31, 275
  21. 10.1136/pgmj.46.538.537 · doi:10.1136/pgmj.46.538.537
  22. Selroos, 1979, Corticosteroid therapy of pulmonary sarcoidosis, Scand J Respir Dis, 60, 215
  23. 10.1016/0002-9343(66)90216-6 · doi:10.1016/0002-9343(66)90216-6
  24. Rossman, 2006, A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 23, 201
  25. 10.1001/archinte.1995.00430080088011 · doi:10.1001/archinte.1995.00430080088011
  26. Fang, 2019, Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study, Sarcoidosis Vasc Diffuse Lung Dis, 36, 217
  27. Siltzbach, 1964, Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis, Acta Med Scand, 425, 302S, 10.1111/j.0954-6820.1964.tb05780.x · doi:10.1111/j.0954-6820.1964.tb05780.x
  28. Minnis, 2016, Adalimumab for refractory pulmonary sarcoidosis, Ir J Med Sci, 185, 969, 10.1007/s11845-015-1363-9 · doi:10.1007/s11845-015-1363-9
  29. 10.1183/09031936.00224513 · doi:10.1183/09031936.00224513
  30. Drake, 2013, Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 30, 201
  31. Drake, 2021, Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis, Chest, 159, 1902, 10.1016/j.chest.2020.12.027 · doi:10.1016/j.chest.2020.12.027
  32. Irwin, 2018, Higher priced older pharmaceuticals: how should we respond?, Chest, 153, 23, 10.1016/j.chest.2017.09.042 · doi:10.1016/j.chest.2017.09.042
  33. 10.1016/j.ccm.2015.08.010 · doi:10.1016/j.ccm.2015.08.010
  34. 10.1001/archdermatol.2011.2085 · doi:10.1001/archdermatol.2011.2085
  35. Chang, 2012, Cutaneous sarcoidosis: a case series from a regional hospital in Hong Kong, Hong Kong J Dermatol Venereol, 20, 153
  36. Tong, 2014, Comparison of cutaneous sarcoidosis with systemic sarcoidosis: a retrospective analysis, Int J Clin Exp Pathol, 7, 372
  37. Collin, 2010, A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department, Clin Exp Dermatol, 35, 131, 10.1111/j.1365-2230.2009.03400.x · doi:10.1111/j.1365-2230.2009.03400.x
  38. Volden, 1992, Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing, Acta Derm Venereol, 72, 69, 10.2340/00015555726971 · doi:10.2340/00015555726971
  39. 10.1001/archderm.131.5.617 · doi:10.1001/archderm.131.5.617
  40. 10.1016/j.jaad.2006.06.019 · doi:10.1016/j.jaad.2006.06.019
  41. Noe, 2017, High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 34, 136
  42. Droitcourt, 2014, A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis, Chest, 146, 1046, 10.1378/chest.14-0015 · doi:10.1378/chest.14-0015
  43. 10.1016/S0041-3879(67)80033-3 · doi:10.1016/s0041-3879(67)80033-3
  44. Jones, 1990, Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas, J Am Acad Dermatol, 23, 487, 10.1016/0190-9622(90)70246-E · doi:10.1016/0190-9622(90)70246-e
  45. 10.1016/0190-9622(91)70071-9 · doi:10.1016/0190-9622(91)70071-9
  46. 10.1016/S0022-3476(97)70306-8 · doi:10.1016/s0022-3476(97)70306-8
  47. Rajendran, 1994, Methotrexate in the treatment of cutaneous sarcoidosis, Sarcoidosis, 11, S335
  48. 10.1016/j.jcmg.2017.04.020 · doi:10.1016/j.jcmg.2017.04.020
  49. Chapelon-Abric, 2017, Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors, Arch Cardiovasc Dis, 110, 456, 10.1016/j.acvd.2016.12.014 · doi:10.1016/j.acvd.2016.12.014
  50. Takaya, 2014, Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement, Int J Cardiol, 176, 522, 10.1016/j.ijcard.2014.07.042 · doi:10.1016/j.ijcard.2014.07.042
  51. Fujita, 1990, A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities, Heart Vessels Suppl, 5, 16
  52. 10.2174/1573403X15666190725121246 · doi:10.2174/1573403x15666190725121246
  53. Joubert, 2017, Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis, JAMA Neurol, 74, 1336, 10.1001/jamaneurol.2017.2492 · doi:10.1001/jamaneurol.2017.2492
  54. 10.1186/s12883-016-0741-x · doi:10.1186/s12883-016-0741-x
  55. 10.1001/archinte.1997.00440370104011 · doi:10.1001/archinte.1997.00440370104011 · Paper page
  56. Metyas, 2014, Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab, Int J Rheum Dis, 17, 214, 10.1111/1756-185X.12122 · doi:10.1111/1756-185x.12122
  57. 10.1378/chest.124.5.2023 · doi:10.1378/chest.124.5.2023
  58. Thunold, 2017, Patient reported outcome measures (PROM) in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 34, 2
  59. Voortman, 2018, Determinaton of the smallest detectable change and minimal important change (MIC) for the small fiber neuropathy screening list (SFNSL) in sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 35, 333
  60. Lower, 2019, Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome, Sarcoidosis Vasc Diffuse Lung Dis, 36, 254

Cited by

See all 629

Metadata

Authors
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., Israel-Biet, D., Grutters, J. C., Drent, M., Culver, D. A., Bonella, F., Antoniou, K., Martone, F., Quadder, B., Spitzer, G., Nagavci, B., Tonia, T., Rigau, D., & Ouellette, D. R.
Venue
European Respiratory Journal
Published
2021-06-17
Volume
58
Issue
6
Pages
2004079
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W3166756865
Cited by
629
References
184
FWCI
50.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.